IP Library › Granted Patent US 12,582,730
Granted Patent B2
US 12,582,730 · App. 17/918,160 · Granted Mar 24, 2026

Electroporation devices and methods

Inventors: Hideki Ebihara (Rochester, MN); Jason A. Tri (Rochester, MN); Kalpathi L. Venkatachalam (Jacksonville Beach, FL); Paul A. Friedman (Rochester, MN); Christopher V. DeSimone (Rochester, MN); Daniel C. DeSimone (Rochester, MN); Martin van Zyl (Rochester, MN); Adetola O. Ladejobi (Rochester, MN); Andrew D. Badley (Rochester, MN); Samuel J. Asirvatham (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
A61L2/03A61M1/3472A61M16/0402
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,730
App. No.
17/918,160
Granted
Mar 24, 2026
Kind
B2
Abstract

Devices and methods are described for disinfection of pathogenic organisms using pulsed DC field electroporation. For example, this disclosure describes disinfection of pathogenic organisms using pulsed DC field electroporation for lung infection treatment, blood infection treatment, sterilization, and respirators.

Claims (14)

1 . A system for treatment of lung infections of a patient, the system comprising:

an endotracheal tube;

a first electrode that is advanceable along the endotracheal tube;

a second electrode configured for placement on an exterior chest wall of the patient;

a source of particulate aerosols, the source configured to introduce the particulate aerosols into airways of the patient via the endotracheal tube;

a power source configured to deliver energy to the first electrode that causes the first electrode to emit pulse electroporation fields; and

a monitor configured to track airway pressure and to discontinue delivery of energy in response to a change in plateau or peak airway pressures.

2 . The system of claim 1 , wherein the particulate aerosols comprise humidified or conducting particles configured to enhance efficacy of the pulse electroporation fields.

3 . The system of claim 1 , wherein the first electrode is configured to be positioned near the carina of the patient.

4 . The system of claim 1 , wherein the power source is configured to deliver pulsed energy at a voltage between 1 kilovolt and 20 kilovolts and a pulse duration of about 1 millisecond.

5 . The system of claim 1 , wherein the source of particulate aerosols comprises an aerosolized fluid source configured to inject aerosolized liquid selected from saline and distilled water into the endotracheal tube.

6 . The system of claim 1 , wherein the second electrode comprises a pair of return electrodes dimensioned for placement on respective left and right chest walls of the patient.

7 . The system of claim 1 , wherein the first electrode includes a distal portion positionable adjacent a carina of the patient when advanced along the endotracheal tube.

8 . The system of claim 1 , wherein the power source comprises a pulsed direct-current field generator.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2022
From: EBIHARA, HIDEKI; TRI, JASON A.; VENKATACHALAM, KALPATHI L.; FRIEDMAN, PAUL A.; DESIMONE, CHRISTOPHER V.; DESIMONE, DANIEL C.; ZYL, MARTIN VAN; LADEJOBI, ADETOLA O.; BADLEY, ANDREW D.; ASIRVATHAM, SAMUEL J.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 062227/0138 →
Continuity (2)
Provisional Application 63009342 · Apr 13, 2020
Related Publication 20230139966A1 · May 4, 2023
References Cited (39)
US 5634899A · Shapland et al. · 1997 [cited by applicant]
US 5865787A · Shapland et al. · 1999 [cited by applicant]
US 6264975B1 · Boucher, Jr. · 2001 [cited by applicant]
US 7113821B1 · Sun et al. · 2006 [cited by applicant]
US 9351790B2 · Zemel et al. · 2016 [cited by applicant]
US 10828462B2 · Daniels et al. · 2020 [cited by applicant]
US 20090143761A1 · Cantor et al. · 2009 [cited by applicant]
US 20090253714A1 · Johnson et al. · 2009 [cited by applicant]
US 20120089078A1 · Deem et al. · 2012 [cited by applicant]
US 20150182282A1 · Zemel et al. · 2015 [cited by applicant]
US 20150328449A1 · Soden et al. · 2015 [cited by applicant]
US 20170095628A1 · Bartlett, II et al. · 2017 [cited by applicant]
US 20180296264A1 · DeSimone et al. · 2018 [cited by applicant]
US 20190030328A1 · Stewart et al. · 2019 [cited by applicant]
US 20190231425A1 · Waldstreicher et al. · 2019 [cited by applicant]
US 20190282290A1 · Wolf et al. · 2019 [cited by applicant]
US 20210146126A1 · Waldstreicher et al. · 2021 [cited by applicant]
US 20220047686A1 · Asirvatham et al. · 2022 [cited by applicant]
DE 102012025164A1 · 2014 [cited by applicant]
DE 102014010907A1 · 2016 [cited by applicant]
EP 0785987B1 · 1999 [cited by applicant]
WO WO9421117A1 · 1994 [cited by applicant]
WO WO2003013615 · 2003 [cited by applicant]
WO WO2007046757A1 · 2007 [cited by applicant]
WO WO2017173089A1 · 2017 [cited by applicant]
WO WO2018005511 · 2018 [cited by applicant]
WO WO2019133606 · 2019 [cited by applicant]
WO WO2023076046A1 · 2023 [cited by applicant]
Cheng et al., “Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19,” J. Med. Virol., Jul. 2020, 92(7):726-730. [cited by applicant]
Colalto, “Volatile molecules for COVID-19: A possible pharmacological strategy?,” Drug Dev. Res., Dec. 2020, 81(8):950-968. [cited by applicant]
Klimke et al., “Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-COV-2 infection,” Med. Hypotheses, Sep. 2020, 142(109783):1-4. [cited by applicant]
Extended European Search Report in European Appln No. 21787717.4, dated Aug. 14, 2023, 7 pages. [cited by applicant]
Al-Jumaili et al., “Review on the Antimicrobial Properties of Carbon Nanostructures,” Materials, Sep. 2017, 10(9):1066, 26 pages. [cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2021/026854, mailed on Oct. 27, 2022, 6 pages. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2021/026854, mailed on Sep. 1, 2021, 8 pages. [cited by applicant]
The New York Times [online], “As Coronavirus Looms, Mask Shortage Gives Rise to Promising Approach,” Mar. 20, 2020, retrieved on Feb. 22, 2022, retrieved from URL<https://www.nytimes.com/2020/03/20/health/coronavirus-ma… [cited by applicant]
Velebit et al., “Non-thermal inactivation of Noroviruses in food,” Presented at Proceedings of the 59th International Meat Industry Conference MEATCON2017, Mt. Zlatibor, Serbia, Oct. 1-4, 2017; Conference Series: Earth … [cited by applicant]
Viruses in Food, 2nd ed., Goyal et al. (eds.), Aug. 2016, Chapter 15, 27 pages. [cited by applicant]
Extended European Search Report in European Appln. No. 25175503.9, mailed on Aug. 19, 2025, 8 pages. [cited by applicant]